Welcome to our dedicated page for ANBIO BIOTECHNOLOGY news (Ticker: NNNN), a resource for investors and traders seeking the latest updates and insights on ANBIO BIOTECHNOLOGY stock.
Anbio Biotechnology (NNNN) is a global in vitro diagnostics company whose news flow centers on product launches, technology platforms and capital markets activity in the medical instruments and supplies sector. The company focuses on IVD solutions for point-of-care, laboratory and over-the-counter use, spanning immunofluorescence, dry chemistry, chemiluminescence, molecular diagnostics, rapid tests and veterinary diagnostics.
Recent announcements highlight Anbio’s role in outbreak response and decentralized molecular testing. The company has introduced a Chikungunya IgM/IgG Rapid Test based on immunochromatographic technology for qualitative detection of Chikungunya-specific antibodies in human serum, plasma or whole blood, supporting clinicians and public health authorities in differentiating Chikungunya from other arboviral infections at the point of care. Anbio has also unveiled the AP-100 Ultra-Fast PCR system, a compact platform that, according to the company, delivers PCR results in about 15 minutes from raw samples using microfluidic thermal cycling and an extraction-free workflow, with coverage for respiratory pathogens such as COVID-19, Flu A/B, RSV, MP and ADV.
Other news items cover Anbio’s participation in major international exhibitions, where it showcases fluorescence immunoassay systems, dry chemistry analyzers, rapid test kits, molecular diagnostic systems and a veterinary diagnostics suite. These updates reflect its global presence across the EU, APAC and the Americas and its strategy of expanding product registrations and partnerships in over 100 countries.
Investors and healthcare professionals can use this page to follow Anbio’s latest press releases on new assays, platform enhancements, global exhibitions and financing milestones such as its Nasdaq Global Market initial public offering, helping them track how the company develops and deploys its diagnostic technologies over time.
Anbio Biotechnology (NASDAQ: NNNN) announced its CEO will participate in the KeyBanc Capital Markets Virtual Healthcare Forum on March 18, 2026. The session is a fireside chat where the CEO will discuss previously disclosed business updates, strategic initiatives, and product development with investors.
The appearance underscores Anbio's engagement with the investment community and its focus on broadening access to rapid diagnostics and advancing its product pipeline.
Anbio Biotechnology has announced two significant product launches to address global disease outbreaks. The company introduced a Chikungunya IgM/IgG Rapid Test for detecting Chikungunya fever antibodies in human samples, addressing the rising cases in tropical regions.
Additionally, Anbio launched the AP-100 Ultra-Fast PCR system, a revolutionary point-of-care diagnostic tool that delivers results in 15 minutes. The compact 668g device features an extraction-free workflow and covers multiple pathogens including COVID-19, Flu A/B, RSV, MP, and ADV. The company plans to expand its testing capabilities to include tuberculosis and HPV diagnostics.
Anbio Biotechnology announces its participation in three major international exhibitions in May 2025: EuroMedLab (Brussels), AVA Conference (Sydney), and ACMTT (Bangkok). The company will showcase its comprehensive diagnostic portfolio including:
- Fluorescence Immunoassay Systems supporting 90 test items
- Dry Chemistry Analyzers for point-of-care biochemical testing
- Rapid Test Kits for on-site diagnostics
- Molecular Diagnostic System featuring LAMP-based technology
- Veterinary Diagnostics Suite for companion animal health
With product registrations in over 100 countries, Anbio is actively seeking distribution partners, research collaborators, and strategic investors to expand its global presence in both human and animal healthcare diagnostics.
Anbio Biotechnology has successfully completed its Initial Public Offering (IPO) on the Nasdaq Global Market under the ticker symbol 'NNNN'. The company offered 1,600,000 Class A ordinary shares at $5.00 per share, raising gross proceeds of $8 million before deducting underwriting discounts and related expenses.
Trading commenced on February 19, 2025. The proceeds will be used for expanding sales and distribution networks in strategic markets, research and development initiatives, and working capital purposes. AC Sunshine Securities served as the underwriter for this firm commitment offering.
The IPO was supported by a Form F-1 registration statement filed with the SEC, which became effective on February 18, 2025. Ortoli Rosenstadt LLP and Focus Law served as legal counsel to the company and underwriter, respectively.
Anbio Biotechnology, a global diagnostic company focused on medical technology and in vitro diagnostics, has announced the pricing of its Initial Public Offering (IPO). The company is offering 1,600,000 Class A ordinary shares at $5.00 per share, expecting to raise gross proceeds of $8 million.
Trading is set to commence on February 19, 2025, on the Nasdaq Global Market under the ticker symbol NNNN. The offering is expected to close around February 20, 2025. AC Sunshine Securities is serving as the underwriter for this firm commitment offering.
The proceeds will be allocated towards expanding sales and distribution networks in strategic markets, research and development initiatives, and general working capital purposes.